Paes-De-Carvalho R. Adenosine as a signaling molecule in the retina: Biochemical and developmental aspects. An Acad Bras Cienc 2002; 74(3): 437-51.
Bieber D, Lorenz K, Yadav R, Klotz KN. A2B adenosine receptors mediate an inhibition of ERK-1/2 phosphorylation in the breast cancer cell line MDA-MB-231. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 1-98.
Willingham S, Ho P, Leone R, et al. The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1. abstract Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. 2016 Apr 16-20; New Orleans, LA. 2016.
Borodovsky A, Wang Y, Ye M, et al. Inhibition of A R by AZD4635 induces anti-tumor immunity alone and in combination with anti-PDL1 in preclinical models [abstract] Proceedings of the American Association for Cancer Research Annual Meeting. 2018 Apr 14-18; Chicago, IL. 2018.
Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, Baraldi PG. Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. In: PAdenosine Receptors in Health and Disease: Springer Berlin Heidelberg. 123-59. 2009; pp.
Leung E. The use of adenosine A3 receptor antagonists to inhibit tumor growth. WO Patent 200001039: 2000.
Baraldi PG, Borea PA. Adenosine A3 receptor modulators. WO Patent 2003095457: 2003.
Borea PA, Leung E, Chen SF, Baraldi PG. Enhancing treatment of MDR cancer with adenosine A3 antagonists. WO Patent 2004000224: 2003.
Sachsenmeier K, Poon E, Sult E, Hay C. Therapeutic combinations comprising anti-CD73 antibodies and A2A receptor inhibitor and uses thereof. WO2016075176: 2016.